Additional Proxy Soliciting Materials (definitive) (defa14a)
May 08 2017 - 4:34PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(Rule
14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )
Filed by the Registrant ☒
Filed by
a Party other than the Registrant ☐
Check the appropriate box:
☐
|
Preliminary Proxy Statement
|
☐
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
☐
|
Definitive Proxy Statement
|
☒
|
Definitive Additional Materials
|
☐
|
Soliciting Material under §240.14a-12
|
ACHILLION PHARMACEUTICALS, INC.
(Name of Registrant as Specified In
Its Charter)
(Name of Person(s) Filing Proxy
Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
☐
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|
(1)
|
Title of each class of securities to which transaction applies:
|
|
(2)
|
Aggregate number of securities to which transaction applies:
|
|
(3)
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
|
|
(4)
|
Proposed maximum aggregate value of transaction:
|
☐
|
Fee paid previously with preliminary materials.
|
☐
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.
|
|
(1)
|
Amount Previously Paid:
|
|
(2)
|
Form, Schedule or Registration Statement No.:
|
ACHILLION PHARMACEUTICALS, INC.
300 George Street
New
Haven, Connecticut 06511
SUPPLEMENT TO THE PROXY STATEMENT FOR
THE ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON MAY 23, 2017
May 8, 2017
These
Definitive Additional Materials amend and supplement the definitive proxy statement, dated April 17, 2017 (the 2017 Proxy Statement), of Achillion Pharmaceuticals, Inc. for its 2017 Annual Meeting of Stockholders to be held at 300
George Street, New Haven, Connecticut 06511 on Tuesday, May 23, 2017 at 9:00 a.m., local time.
SUPPLEMENT TO DEFINITIVE PROXY STATEMENT
This supplemental information should be read in conjunction with the 2017 Proxy Statement, which should be read in its entirety.
On May 8, 2017, Michael D. Kishbauch, a member of the Board of Directors (the Board) of Achillion Pharmaceuticals, Inc.,
notified the Board of his resignation from the Audit Committee and the Nominating and Corporate Governance Committee, effective immediately. Mr. Kishbauch will continue to serve on the Board.
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Sep 2023 to Sep 2024